"UPenn's Trial: BRCA Cancer Vaccine Tested on Healthy Individuals"
The University of Pennsylvania and Inovio Pharmaceuticals are conducting a clinical trial for a vaccine aimed at preventing cancer in individuals with the BRCA gene mutation, which significantly increases the risk of breast, ovarian, prostate, and pancreatic cancer. The vaccine uses DNA and electric shocks to train the immune system to recognize and attack abnormal cells before they develop into tumors. The trial has drawn significant interest and could potentially offer a less invasive and more effective alternative to preventive surgeries and ongoing screening for those at high risk of hereditary cancer.